- Did you mean
- determination
Search results - 7 results
Assessment of the clinical and analytical performance of the Aptima SARS-CoV-2 assay using the VALCOR protocol.
of 180 clinical samples were tested with an addition of 40 diluted clinical specimens to determine the limit of detection. When compared to the standard comparator assay Aptima had a sensitivity of ...
Citizens' conceptions of the genome: Related values and practical implications in a citizen forum on the use of genomic information
four conceptions of the genome that determined which uses of genomic information they supported: the most intimate part of individuals; ‘I am more than my genome’; the individual’s property vs the common ...
Might Oral Human Papillomavirus (HPV) Infection in Healthy Individuals Explain Differences in HPV-Attributable Fractions in Oropharyngeal Cancer? A Systematic Review and Meta-analysis.
healthy populations. Consistent research on determinants of oral HPV prevalence, acquisition, clearance, and persistence is warranted. Health Topics: Cancer Cancer Kanker Service: Centre du cancer ...
The EMPCAN study: protocol of a population-based cohort study on the evolution of the socio-economic position of workers with cancer
Issue 1 (2019) Keywords: cancer Determining factors Life course Return-to-work Abstract: Background: The improvements in cancer control led to an increase in the number of cancer survivors, notably, in ...
Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
Tests) and aims to determine whether the reproducibility of Xpert HPV is in line with international validation criteria. METHODS Validation of new hrHPV DNA assays requires demonstration of good ...
Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework.
hrHPV determined by INNO-LiPA was 17.1% (95% CI, 15.0⁻19.2%) in the screening population. HrHPV testing with INNO-LiPA had a sensitivity for CIN2 + of 96.9% (95% CI, 92.1⁻99.1%) which was non-inferior to ...
Barriers to and facilitators of compliance with clinic-based cervical cancer screening: population-based cohort study of women aged 23-60 years.
travel costs and other direct non-medical costs incurred in attending clinic-based cervical cancer screening, (b) investigating screening compliance and reasons for noncompliance, (c) determining women’s ...